AltruBio

Executive Summary

AltruBio is a clinical-stage biotechnology company developing first-in-class immunomodulators targeting the PSGL-1 pathway to regulate T-cell homeostasis for the treatment of immunological and inflammatory diseases. Based in San Francisco, the company’s lead program, ALTB-268, is a potency-improved antibody currently in Phase 2a clinical trials for ulcerative colitis. By modulating the PSGL-1 pathway, AltruBio aims to provide safer and more durable treatments compared to existing therapies, which often suffer from limited efficacy or significant side effects. The company’s approach addresses a key unmet need in autoimmune diseases, where durable remission remains elusive for many patients. AltruBio’s pipeline also includes earlier-stage programs targeting other inflammatory conditions, though ALTB-268 represents its most advanced asset. As a private company, AltruBio has not disclosed its total funding or valuation, but its innovative mechanism and initial clinical data position it as a potential emerging player in the immunology space. The upcoming Phase 2a data readout for ALTB-268 will be a critical inflection point, determining the program’s path toward later-stage trials and potential partnership interest.

Upcoming Catalysts (preview)

• Q3 2026Phase 2a interim data readout for ALTB-268 in ulcerative colitis60% success
• TBDPotential partnership or licensing deal for ALTB-26850% success
• Q4 2026Series B or follow-on financing round to support Phase 2/3 development70% success